| Drug Name |
Guanfacine hydrochloride |
| Drug ID |
BADD_D01047 |
| Description |
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an extended release tablet for the treatment of ADHD.[L11277] Guanfacine was first described in the literature in 1974.[A189841]
Guanfacine was granted FDA approval on 27 October 1986.[L11274] |
| Indications and Usage |
Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.[L11277] |
| Marketing Status |
approved; investigational |
| ATC Code |
C02AC02 |
| DrugBank ID |
DB01018
|
| KEGG ID |
D00606
|
| MeSH ID |
D016316
|
| PubChem ID |
71401
|
| TTD Drug ID |
D0WD8M
|
| NDC Product Code |
46016-2911; 63552-021; 65372-1177; 70518-3516; 46016-2912; 53747-096; 53069-0080; 63190-0250; 53296-0024; 63552-023; 63552-022; 60687-710; 42291-310; 63552-024; 68071-2719; 29300-458; 29300-459 |
| UNII |
PML56A160O
|
| Synonyms |
Guanfacine | Tenex | Guanfacine Hydrochloride | Hydrochloride, Guanfacine | Guanfacine Monohydrochloride | Monohydrochloride, Guanfacine | Lon798 | BS-100-141 | BS 100 141 | BS100141 | Estulic |
